The first aspect investigated in this study was the evaluation of whether mTORC1 inhibition could remove the inhibitory loop on ERK1/2 in AML cell lines, as shown by Carracedo et al. with respect to other tumor types [22]. The gene discussed is MAPK3; the disease is acute myeloid leukemia.